Prospective validation of an uncertainty-aware machine learning model for secondary progressive multiple sclerosis classification
Parakkal Sreenivasan, A.; Noui, Y.; Erngren, I.; Spjuth, O.; Burman, J.; Kultima, K.
Show abstract
Background: Relapsing-remitting multiple sclerosis (RRMS) often progresses to secondary-progressive MS (SPMS), but diagnosis is typically retrospective, delaying potential interventions. Existing rule-based and machine learning approaches often lack prospective validation and provide no uncertainty estimates, limiting clinical adoption. Objective: To prospectively evaluate a conformal prediction (CP)-enabled random forest model for reproducing clinician-recorded disease course labels in the Swedish Multiple Sclerosis Registry (SMSReg) and compare its classifications with the Lorscheider criteria. Methods: The CP model was trained and calibrated on SMSReg-2022 (10,787 individuals, 85,461 hospital visits) and then validated on SMSReg-2025 (15,719 individuals, 45,077 hospital visits; not included in the SMSReg-2022 training/calibration/testing datasets). Performance was assessed at the hospital visit and individual levels and compared with the Lorscheider criteria. Results: The model maintained good calibration on the prospective dataset. At the per-hospital visit-level, the model accuracies were 92% (RRMS) and 95% (SPMS). At the individual level, sensitivity was 98%, specificity 89%, and F1-score 0.75. With clinician-recorded labels as reference, the model showed higher sensitivity than the Lorscheider criteria (98% vs. 71%), more transition assignments (90% vs. 57%), and higher F1-score (0.76 vs. 0.69). Conclusion: The CP-enabled model prospectively reproduced clinician-recorded disease course labels with calibrated uncertainty, supporting harmonization and decision support.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Accurate classification of secondary progression in multiple sclerosis 94%
- Creating an automated tool for a consistent and repeatable evaluation of disability progression in clinical studies for Multiple Sclerosis 92%
- The relationship between ethnicity and Multiple Sclerosis characteristics in the United Kingdom: a UK MS Register study 91%
Similar papers in this journal
- The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis 93%
- Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model 92%
- Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland 91%
Similar papers in this journal
- Genetic subtypes predict multiple sclerosis severity and response to treatment 93%
- Diffusivity anisotropy signature of the slowly expanding lesions predicts progression independent of relapse activity in multiple sclerosis 89%
- Predicting disability progression and cognitive worsening in multiple sclerosis using grey matter network measures 88%
Similar papers in this journal
Similar papers in this journal
- Current status and future opportunities in modeling Multiple Sclerosis clinical characteristics 93%
- Alpha-Linolenic Acid Associations with Disability and Brain Volume in Multiple Sclerosis: A Brief Replication Report 91%
- The Canadian Collaborative Project on Genetic Susceptibility to Multiple Sclerosis cohort population structure and disease etiology 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.